BIT Capital GmbH Increases Position in Autolus Therapeutics plc (NASDAQ:AUTL)

BIT Capital GmbH lifted its holdings in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 147.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 636,979 shares of the company's stock after purchasing an additional 379,050 shares during the quarter. BIT Capital GmbH owned about 0.24% of Autolus Therapeutics worth $1,497,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Wellington Management Group LLP boosted its holdings in shares of Autolus Therapeutics by 35.4% in the 3rd quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company's stock valued at $87,919,000 after purchasing an additional 6,330,392 shares in the last quarter. FMR LLC lifted its stake in shares of Autolus Therapeutics by 44.6% in the third quarter. FMR LLC now owns 17,773,873 shares of the company's stock valued at $64,519,000 after buying an additional 5,478,706 shares in the last quarter. Candriam S.C.A. bought a new stake in Autolus Therapeutics during the 4th quarter worth approximately $7,500,000. JPMorgan Chase & Co. grew its stake in shares of Autolus Therapeutics by 145.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,284,708 shares of the company's stock worth $4,663,000 after acquiring an additional 761,008 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. bought a new position in shares of Autolus Therapeutics during the fourth quarter valued at about $611,000. Institutional investors and hedge funds own 72.83% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Needham & Company LLC reiterated a "buy" rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research note on Monday, January 13th. Wells Fargo & Company cut their price target on shares of Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating for the company in a report on Friday, March 21st. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $9.52.

Autolus Therapeutics Price Performance

Shares of AUTL traded down $0.13 on Monday, reaching $1.54. The company's stock had a trading volume of 950,181 shares, compared to its average volume of 1,214,771. The stock's 50 day simple moving average is $1.96 and its two-hundred day simple moving average is $2.81. The stock has a market capitalization of $408.45 million, a P/E ratio of -1.27 and a beta of 2.07. Autolus Therapeutics plc has a 12-month low of $1.52 and a 12-month high of $6.31.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings results on Thursday, March 20th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.12. The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $2.98 million. Analysts expect that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.